Tanzeum Purple Book BLA 125431

BLA number
125431
Proprietary names
Tanzeum
Proper names
albiglutide
Applicant
GlaxoSmithKline LLC
Center
CDER
First observed release
2020-05-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001Tanzeumalbiglutide351(a)30MGFor InjectionSubcutaneousAutoinjectorDiscVoluntarily Revoked2014-04-15
002Tanzeumalbiglutide351(a)50MGFor InjectionSubcutaneousAutoinjectorDiscVoluntarily Revoked2014-04-15

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2020-10-01U001Tanzeum351(a)DiscGlaxoSmithKline LLC
2020-10-01U002Tanzeum351(a)DiscGlaxoSmithKline LLC
2020-05-01R001Tanzeum351(a)RxGlaxoSmithKline LLC
2020-05-01R002Tanzeum351(a)RxGlaxoSmithKline LLC

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2020-10-01001Tanzeum351(a)DiscVoluntarily Revoked2014-04-15
2020-10-01002Tanzeum351(a)DiscVoluntarily Revoked2014-04-15
2020-05-01001Tanzeum351(a)RxLicensed2014-04-15
2020-05-01002Tanzeum351(a)RxLicensed2014-04-15